Loading...
XNASGYRE
Market cap857mUSD
Jan 13, Last price  
9.99USD
1D
3.85%
1Q
-24.26%
IPO
48.44%
Name

Catalyst Biosciences Inc

Chart & Performance

D1W1MN
XNAS:GYRE chart
P/E
—
P/S
7.56
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
42.47%
Rev. gr., 5y
616.69%
Revenues
113m
+14,188.41%
3,738,3741,179,91727,537,56411,575,93120,085,00025,062,00085,713,00097,637,00057,860,0003,629,000275,0001,750,000399,0001,018,0006,000020,948,0007,338,000794,000113,450,000
Net income
-93m
L
-24,025,389-28,991,5232,096,529-28,072,887-25,661,000-39,404,00010,899,000-8,529,000-6,998,000-46,705,000-32,623,000-14,762,000-16,945,000-21,561,000-30,055,000-52,887,000-55,542,000-87,933,0002,302,000-92,933,000
CFO
26m
P
-25,036,628-26,246,516-9,892,27724,838,076-28,261,000-24,271,000138,298,000-83,718,000-64,239,000-40,612,000-34,483,000-19,118,000-18,472,000-19,940,000-28,553,000-43,613,000-55,048,000-83,755,000-33,096,00025,892,000
Dividend
Jan 13, 20230.24 USD/sh
Earnings
Mar 24, 2025

Profile

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
URL
https://www.catalystbiosciences.com/
IPO date
Apr 12, 2006
Employees
7
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
113,450
14,188.41%
794
-89.18%
Cost of revenue
94,237
85,439
Unusual Expense (Income)
NOPBT
19,213
(84,645)
NOPBT Margin
16.94%
Operating Taxes
8,515
348
Tax Rate
44.32%
NOPAT
10,698
(84,993)
Net income
(92,933)
-4,137.05%
2,302
-102.62%
Dividends
(45,031)
Dividend yield
Proceeds from repurchase of equity
2,500
20
BB yield
Debt
Debt current
210
38
Long-term debt
608
159
Deferred revenue
213
118
Other long-term liabilities
17,606
33,309
Net debt
(56,122)
(28,863)
Cash flow
Cash from operating activities
25,892
(33,096)
CAPEX
(8,517)
(4,998)
Cash from investing activities
(19,760)
55,426
Cash from financing activities
2,500
(45,011)
FCF
(21,938)
(81,349)
Balance
Cash
33,509
21,666
Long term investments
23,431
7,394
Excess cash
51,268
29,020
Stockholders' equity
10,295
(345,627)
Invested Capital
86,407
355,423
ROIC
4.84%
ROCE
19.87%
EV
Common stock shares outstanding
65,832
75,686
Price
Market cap
EV
EBITDA
20,327
(84,415)
EV/EBITDA
Interest
717
Interest/NOPBT